Li Gong

12.0k total citations · 8 hit papers
85 papers, 6.3k citations indexed

About

Li Gong is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Li Gong has authored 85 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 18 papers in Pharmacology and 12 papers in Oncology. Recurrent topics in Li Gong's work include Pharmacogenetics and Drug Metabolism (16 papers), Genomics and Rare Diseases (6 papers) and Inflammatory mediators and NSAID effects (6 papers). Li Gong is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Genomics and Rare Diseases (6 papers) and Inflammatory mediators and NSAID effects (6 papers). Li Gong collaborates with scholars based in United States, China and Taiwan. Li Gong's co-authors include Teri E. Klein, Russ B. Altman, Michelle Whirl‐Carrillo, Caroline F. Thorn, Katrin Sangkuhl, Joan M. Hebert, Ellen M. McDonagh, Clifford Nass, Mia Wadelius and Kathleen M. Giacomini and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Li Gong

79 papers receiving 6.1k citations

Hit Papers

Pharmacogenomics Knowledg... 2011 2026 2016 2021 2012 2011 2017 2021 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pharmacogenomics Knowledge for Personalized Medicine
    2012 1.3k citations Michelle Whirl‐Carrillo, Li Gong et al. Clinical Pharmacology & Therapeutics profile →
  2. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
    2011 473 citations Li Gong, Michelle Whirl‐Carrillo et al. Clinical Pharmacology & Therapeutics profile →
  3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
    2017 435 citations Li Gong, Michelle Whirl‐Carrillo et al. Clinical Pharmacology & Therapeutics profile →
  4. An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine
    2021 410 citations Michelle Whirl‐Carrillo, Rachel Huddart et al. Clinical Pharmacology & Therapeutics profile →
  5. Metformin pathways
    2012 380 citations Li Gong, Kathleen M. Giacomini et al. Pharmacogenetics and Genomics profile →
  6. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update
    2014 301 citations Laura B. Ramsey, Samuel G. Johnson et al. Clinical Pharmacology & Therapeutics profile →
  7. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs
    2020 208 citations Li Gong, Kelly E. Caudle et al. Clinical Pharmacology & Therapeutics profile →
  8. PharmVar GeneFocus: CYP2B6
    2021 178 citations Zeruesenay Desta, Li Gong et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Li Gong United States 33 2.4k 1.6k 845 842 742 85 6.3k
Ayako Suzuki United States 45 1.3k 0.6× 1.4k 0.9× 709 0.8× 295 0.4× 423 0.6× 194 9.8k
Stefan Winter Germany 37 895 0.4× 1.3k 0.8× 1.1k 1.4× 399 0.5× 586 0.8× 140 4.8k
Lang Li United States 39 642 0.3× 2.0k 1.3× 1.4k 1.6× 402 0.5× 599 0.8× 158 5.1k
Robert A. Roth United States 49 2.7k 1.2× 1.9k 1.2× 1.1k 1.3× 325 0.4× 144 0.2× 269 8.2k
Brian Tomlinson Hong Kong 57 1.3k 0.5× 2.1k 1.3× 759 0.9× 436 0.5× 579 0.8× 476 13.4k
Ismail Kola Australia 43 523 0.2× 4.0k 2.5× 1.1k 1.3× 488 0.6× 760 1.0× 94 8.1k
Michael J. Sorich Australia 38 779 0.3× 1.8k 1.1× 2.1k 2.4× 292 0.3× 176 0.2× 205 5.7k
M. D. Rawlins United Kingdom 45 1.3k 0.6× 879 0.5× 605 0.7× 1.3k 1.5× 178 0.2× 221 8.6k
Karl E. Anderson United States 54 958 0.4× 3.8k 2.3× 870 1.0× 1.5k 1.7× 962 1.3× 233 8.7k
Philip Lazarus United States 47 1.3k 0.6× 2.6k 1.6× 923 1.1× 550 0.7× 657 0.9× 206 5.8k

Countries citing papers authored by Li Gong

Since Specialization
Citations

This map shows the geographic impact of Li Gong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Gong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Gong more than expected).

Fields of papers citing papers by Li Gong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li Gong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Gong. The network helps show where Li Gong may publish in the future.

Co-authorship network of co-authors of Li Gong

This figure shows the co-authorship network connecting the top 25 collaborators of Li Gong. A scholar is included among the top collaborators of Li Gong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li Gong. Li Gong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caudle, Kelly E., Michelle Whirl‐Carrillo, Mary V. Relling, et al.. (2025). Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC ). Clinical Pharmacology & Therapeutics. 118(6). 1512–1522. 2 indexed citations
2.
Zhang, Yanqing, et al.. (2025). Neuroprotective effects of Gastrodia elata and its compounds in a Caenorhabditis elegans Alzheimer’s disease model. Phytomedicine. 143. 156876–156876. 2 indexed citations
3.
Gong, Li, Michelle Whirl‐Carrillo, Stuart A. Scott, et al.. (2024). P179: The ClinGen Pharmacogenomics Working Group: Developing frameworks for evaluating pharmacogenomic gene validity and actionability. SHILAP Revista de lepidopterología. 2. 101076–101076. 1 indexed citations
4.
Gong, Li, et al.. (2023). From the history of Chinese musical art. OOO Zhurnal Voprosy Istorii. 2023(12-3). 196–201.
5.
Cui, Wei, Li Gong, Christopher Chen, et al.. (2023). [Structural changes of the frontal cortex in depressed mice are associated with decreased expression of brain-derived neurotrophic factor].. PubMed. 43(6). 1041–1046. 1 indexed citations
6.
Gong, Li, Chunyan Wang, Haiyang Xie, et al.. (2022). Identification of a novel heterozygous SOX9 variant in a Chinese family with congenital heart disease. Molecular Genetics & Genomic Medicine. 10(5). e1909–e1909. 6 indexed citations
7.
Whirl‐Carrillo, Michelle, Rachel Huddart, Li Gong, et al.. (2021). An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clinical Pharmacology & Therapeutics. 110(3). 563–572. 410 indexed citations breakdown →
8.
Gong, Li, Juanjuan Wang, Shujing Wang, et al.. (2021). Compound Kushen Injection Protects Skin From Radiation Injury via Regulating Bim. Frontiers in Pharmacology. 12. 753068–753068. 8 indexed citations
9.
10.
11.
Desta, Zeruesenay, Roseann S. Gammal, Li Gong, et al.. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy. PMC. 19 indexed citations
12.
Wang, Meng, et al.. (2017). Age-related changes of leaf traits and stoichiometry in an alpine shrub (Rhododendron agglutinatum) along altitudinal gradient. Journal of Mountain Science. 14(1). 106–118. 13 indexed citations
13.
Gong, Li, et al.. (2015). PharmGKB summary. Pharmacogenetics and Genomics. 25(9). 465–474.
14.
Chen, Jian, et al.. (2013). Spectroscopic Characterization of the Architectural Painting from the Cizhong Catholic Church of Yunnan Province, China. Analytical Letters. 46(14). 2253–2264. 6 indexed citations
15.
Dong, Nianguo, Jinping Liu, Yu Wang, et al.. (2013). Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells. Journal of Huazhong University of Science and Technology [Medical Sciences]. 33(5). 615–622. 32 indexed citations
16.
Wilke, Russell A., Laura B. Ramsey, Samuel G. Johnson, et al.. (2012). The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clinical Pharmacology & Therapeutics. 92(1). 112–117. 242 indexed citations
17.
Yee, Sook Wah, Li Gong, Ilaria Badagnani, et al.. (2010). SLC19A1 pharmacogenomics summary. Pharmacogenetics and Genomics. 20(11). 708–715. 25 indexed citations
18.
Gong, Li. (2007). The boundary of racial prejudice: Comparing preferences for computer-synthesized White, Black, and robot characters. Computers in Human Behavior. 24(5). 2074–2093. 15 indexed citations
19.
Gong, Li. (2007). How social is social responses to computers? The function of the degree of anthropomorphism in computer representations. Computers in Human Behavior. 24(4). 1494–1509. 230 indexed citations
20.
Nass, Clifford & Li Gong. (1999). Maximized Modality or constrained consistency. AVSP. 87(5). 1–64. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ayako Suzuki Breakdown of academic impact, for papers by Stefan Winter Breakdown of academic impact, for papers by Lang Li Breakdown of academic impact, for papers by Robert A. Roth Breakdown of academic impact, for papers by Brian Tomlinson Breakdown of academic impact, for papers by Ismail Kola Breakdown of academic impact, for papers by Michael J. Sorich Breakdown of academic impact, for papers by M. D. Rawlins Breakdown of academic impact, for papers by Karl E. Anderson Breakdown of academic impact, for papers by Philip Lazarus
Rankless by CCL
2026